



CUTISS AG announces that it has been awarded with the prestigious CTI Start up Label on November 7, 2017.

The CTI Start up Label assigns to CUTISS AG the quality status that the company is ready for outside investment and for growth in a sustainable manner.

CUTISS' CEO Dr. Daniela Marino, says: «This achievement honors the hard work of the team in the last years, which has led to matching significant milestones. We appreciate the excellent job CTI is doing in supporting entrepreneurship in Switzerland, nothing would have happened without the contribution of our Coach Jean-Jacques Becciolini.»

About CUTISS AG

CUTISS AG is a Swiss biotech company, spin-off of the UZH, developing personalized skin graft technologies for the treatment of a large spectrum of skin defects. Its first in line product denovoSkin™ has been tested in a Phase I Clinical Trial on pediatric patients at the University Children's Hospital in Zurich. EU Phase IIb Trials are funded by Wyss Zurich. denovoSkin™ has received Orphan Drug Designation for the treatment of burns by Swissmedic, EMA and FDA. In addition, denovoSkin™ promises to improve life quality of elective (reconstructive) patients, it is a scalable technology and it can further be developed in terms of complexity by e.g. adding pigmentation.

Contact

CUTISS AG, Daniela Marino, +41 76 230 8046, info@cutiss.swiss, www.cutiss.swiss